Last update 22 Nov 2025

PKN605

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
PKN605
Target
HDAC6
Action
inhibitors
Mechanism
HDAC6 inhibitors(Histone deacetylase 6 inhibitors), Epigenetic drug
Therapeutic Areas
Cardiovascular Diseases
Active Indication
Atrial Fibrillation
Inactive Indication-
Originator Organization
Novartis Pharma AG
Active Organization
Novartis Pharmaceuticals Canada, Inc.Novartis Pharmaceuticals Canada, Inc.Novartis Pharma AG
Inactive Organization-
License Organization-
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with PKN605
NCT07217067
/ RecruitingPhase 2
A Randomized, Placebo-controlled, Participant- and Investigator-blinded Study to Evaluate the Efficacy in Reducing Atrial Fibrillation Burden (AFB) as Well as the Safety, Tolerability, and Pharmacokinetics of Oral PKN605 in Participants With Atrial Fibrillation
100 Clinical Results associated with PKN605
Login to view more data
100 Translational Medicine associated with PKN605
Login to view more data
100 Patents (Medical) associated with PKN605
Login to view more data
100 Deals associated with PKN605
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Atrial FibrillationPhase 2
United States
Novartis Pharmaceuticals Canada, Inc.Novartis Pharmaceuticals Canada, Inc.
28 Oct 2025
Atrial FibrillationPhase 2
United States
Novartis Pharma AG
28 Oct 2025
Atrial FibrillationPhase 2
China
Novartis Pharma AG
28 Oct 2025
Atrial FibrillationPhase 2
Canada
Novartis Pharmaceuticals Canada, Inc.Novartis Pharmaceuticals Canada, Inc.
28 Oct 2025
Atrial FibrillationPhase 2
Canada
Novartis Pharma AG
28 Oct 2025
Atrial FibrillationPhase 2
Germany
Novartis Pharma AG
28 Oct 2025
Atrial FibrillationPhase 2
Netherlands
Novartis Pharma AG
28 Oct 2025
Atrial FibrillationPhase 2
Netherlands
Novartis Pharmaceuticals Canada, Inc.Novartis Pharmaceuticals Canada, Inc.
28 Oct 2025
Atrial FibrillationPhase 2
Singapore
Novartis Pharmaceuticals Canada, Inc.Novartis Pharmaceuticals Canada, Inc.
28 Oct 2025
Atrial FibrillationPhase 2
Singapore
Novartis Pharma AG
28 Oct 2025
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free